REVIEW : Cannabidiol – Recent Advances Raphael Mechoulam, Maximilian Petersa, Eric Murillo-Rodriguez and Lumïr O. Hanus Chemistry and Biodiversity, 2007, 4, 1678-1692. The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity. Contents 1. Introduction 2. Mechanisms of Cannabidiol Action 2.1. Cannabidiol: an [...]
Lire la suiteLes Phyto-cannabinoïdes Non-psychotropes* : Les nouvelles Opportunités d'une plante ancienne.(*NdT : non-stupéfiants) Angelo A. Izzo, Francesca Borrelli, Raffaele Capasso, Vincenzo Di Marzo and Raphael Mechoulam Trends in Pharmacological Sciences - CELL Press, 2009, 30, 10, 515-27. doi: 10.1016/j.tips.2009.07.006. Le Δ9-tetrahydrocannabinol (Δ9THC) se lie aux récepteurs endocannabinoïdes (CB1 et CB2) qui sont activés par les cannabinoïdes endogènes (endocannabinoïdes) et qui sont impliqués dans une large gamme de processus physiopathologiques (exemple: modulation de la libération de neurotransmetteurs, régulation de la perception de la douleur, régulation des fonctions cardiovasculaires, gastro-intestinales et hépatiques). Les effets psychotropes bien connus du Δ9THC qui sont véhiculés par l'activation des récepteurs CB1 [...]
Lire la suiteRandomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, Orrin Devinsky et al., 2018
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, Matthew H. Wong, Richard Appleton, Cynthia L. Harden, Sam Greenwood, Gilmour Morrison, and Kenneth Sommerville, On behalf of the GWPCARE1 Part A Study Group Neurology® 2018, 0:e1-e8. doi:10.1212/WNL.0000000000005254 Abstract Objective : To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods : Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers [...]
Lire la suiteA Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. G. Morrison, J. Crockett, G. Blakey, K. Sommerville Clinical Pharmacology in Drug Development, 2019, PMID : 30791225, DOI : 10.1002/cpdd.665 Abstract GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; [...]
Lire la suiteVariétés de Cannabis: Par Docteur Ethan Russo http://www.cannabis-med.org/index.php?tpl=faq&red=faqlist&id=172&lng=fr Les consommateurs de cannabis ont souvent indiqué que les différentes variétés de cannabis produisent des effets variables, que se soit concernant les effets psychoactifs ou les bénéfices thérapeutiques. Les variétés sont généralement désignées comme étant soit Sativa, soit Indica, soit hybrides. Or, ces noms, d’un point de vue commercial, prêtent à confusion. Pour cette raison, la communauté scientifique s’est concentrée sur le Tétrahydrocannabinol (THC) qu’elle considérait comme la principale variable et la seule d’importance. En parallèle, jusqu’à très récemment, les croisements sélectifs des variétés de cannabis, destiné à l’usage récréatif ou à l’usage thérapeutique, [...]
Lire la suiteCannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System. Patricia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecilio Hallak, Antonio Waldo Zuardi, Richard B. Parsons, Fabio Klamt CNS Drugs, 2018, 32 (Suppl 1), 1-16 https///doi.org/10.1007/s40263-018-0550-4 Abstract : The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components-cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes-are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural [...]
Lire la suiteStriking lung cancer response to self-administration of cannabidiol : A case report and literature review Josep Sulé-Suso, Nick A Watson, Daniel G van Pittius, Apurna Jegannathen SAGE Open Medical Case Reports, 2019, 7, 1-4. Abstract : In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or reevaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4 Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]
Lire la suiteTake medical use of cannabis seriously, say MEPs Press Releases , Plenary session , ENVI 13-02-2019 - 17:46 http://www.europarl.europa.eu/news/en/press-room/20190207IPR25221/take-medical-use-of-cannabis-seriously-say-meps The EU should stimulate innovation in medical cannabis Effective cannabis-based medicines should be covered by health insurance schemes Authorities should distinguish clearly between medical and other uses www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+20190213+TOC+DOC+XML+V0//EN&language=EN MEPs propose ways to address research gaps on medical cannabis and call on member states to seize the potential of cannabis-based medicines. In a resolution adopted on Wednesday, MEPs call on the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. The resolution urges the Commission and member [...]
Lire la suitePills to Pot : Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain Kevin F. Boehnke, J. Ryan Scott, Evangelos Litinas, Suzanne Sisley, David A. Williams, Daniel J. Clauw The Journal of Pain, 2019 https://www.jpain.org/article/S1526-5900(18)30735-1/fulltext DOI : https://doi.org/10.1016/j.jpain.2019.01.010 Highlights •Medical cannabis users reported substituting cannabis for pain medications. •User rationale for substitution was fewer side effects and better pain management. •Most users reported improved pain and health since using cannabis. •Intentions behind and duration of cannabis use affected substitution behavior. •Unlike previous studies, >50% of participants were women and adults >50 years old. Abstract Chronic pain is common, costly, and challenging to treat. Many [...]
Lire la suite